---
title: "Decidual-like Natural Killer Cells Enriched in Melanoma and CD9 Acquisition via Tumor Contact"
id: "medrxiv-2-decidual-like-natural-killer-cells-are-enriched-in-melanomas-and-acquire-cd9"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-2-decidual-like-natural-killer-cells-are-enriched-in-melanomas-and-acquire-cd9"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.18.26363442v1?rss=1"
published_at: "2026-09-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Decidual-like Natural Killer Cells Enriched in Melanoma and CD9 Acquisition via Tumor Contact
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-2-decidual-like-natural-killer-cells-are-enriched-in-melanomas-and-acquire-cd9
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.18.26363442v1?rss=1)
- **Published At:** 2026-09-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study identifies a population of **decidual-like NK (dl-NK)** cells characterized as CD56Bright CD16− CD49a+ CD9+ within melanoma tumors using flow cytometry and multiplex immunohistochemistry. - These dl-NK cells were rare or absent in peripheral blood from both patients with melanoma and healthy donors, indicating they are primarily intratumoral. - dl-NK cells were found within and adjacent to melanoma tumors from male and female patients, across melanoma subtypes, and at primary, lymph node, and distant metastatic sites. - In an exploratory cohort of patients treated with tumor-infiltrating lymphocyte therapy, one patient with progressive disease had a higher dl-NK frequency; broader outcome correlations were not reported. - Tumor CD9 expression correlated positively with intratumoral dl-NK frequency (Pearson rho = 0.40, p = 0.056), though the p value borders conventional significance thresholds. - Co-culture experiments showed that healthy donor NK cells acquired CD9 when placed in direct contact with CD9-expressing melanoma cells; this acquisition was robust in CD56Bright NK cells. - Use of a transwell to separate NK cells from melanoma cells prevented CD9 acquisition, demonstrating that **direct cell–cell interaction** is required for CD9 transfer. - The findings suggest melanoma cells may induce a decidual-like NK phenotype in situ, implying an immunologic parallel between the melanoma microenvironment and the maternal–fetal interface. - Ethical approvals and sample sources: Colorado Multiple IRB approval, healthy donor PBMCs from Human Immune Tissue Network Biobank, melanoma samples from University of Colorado Cancer Center Melanoma Biorepository. - Funding reported from Golfers Against Cancer and NIH (R21 CA297312, R01 AI158410). Conflicts of interest disclosed for two authors; remaining authors declared no conflicts.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=fj2gktSzcHdDetoQuvK0nn57vRNAnwr891Ng6.Zk7zY-1790037521.5090752-1.2.1.1-Hc7MyXGcH.uf2XgfmndiPckzA0qji8THgPBFcjTlpg0LzbQk.66esEPIhdwPKzSu) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.18.26363442v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Decidual-Like Natural Killer Cells Are Enriched in Melanomas and Acquire CD9 Through Melanoma Cell Contact [ View ORCID Profile](http://orcid.org/0000-0001-5000-8412)Natalie A Vandeven, [ View ORCID Profile](http://orcid.org/0009-0000-0183-3475)Christopher E Collora, [ View ORCID Profile](http://orcid.org/0009-0005-6705-8623)Claire Muckle, [ View ORCID Profile](http://orcid.org/0000-0003-2049-7301)Sofia Celli, [ View ORCID Profile](http://orcid.org/0000-0002-6478-7821)Jessica SW Borgers, [ View ORCID Profile](http://orcid.org/0009-0003-8695-1498)Victoria Sorensen, Katherine Foley, [ View ORCID Profile](http://orcid.org/0000-0002-9817-3043)Katherine M Kichula, [ View ORCID Profile](http://orcid.org/0000-0001-8174-1713)Martin D McCarter, Sapna P Patel, [ View ORCID Profile](http://orcid.org/0000-0002-2088-2229)Kasey L Couts, William A Robinson, [ View ORCID Profile](http://orcid.org/0000-0003-3890-4534)Richard P Tobin, [ View ORCID Profile](http://orcid.org/0000-0001-8370-7703)Paul J Norman doi: https://doi.org/10.64898/2026.09.18.26363442 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Natalie A Vandeven University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Natalie%2BA%2BVandeven%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Vandeven%20NA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANatalie%2BA%2BVandeven%2B) * [ORCID record for Natalie A Vandeven](http://orcid.org/0000-0001-5000-8412 "Open in new tab") * For correspondence: natalie.vandeven88@gmail.com Christopher E Collora University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Christopher%2BE%2BCollora%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Collora%20CE&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChristopher%2BE%2BCollora%2B) * [ORCID record for Christopher E Collora](http://orcid.org/0009-0000-0183-3475 "Open in new tab") Claire Muckle University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Claire%2BMuckle%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Muckle%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AClaire%2BMuckle%2B) * [ORCID record for Claire Muckle](http://orcid.org/0009-0005-6705-8623 "Open in new tab") Sofia Celli University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sofia%2BCelli%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Celli%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASofia%2BCelli%2B) * [ORCID record for Sofia Celli](http://orcid.org/0000-0003-2049-7301 "Open in new tab") Jessica SW Borgers University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jessica%2BSW%2BBorgers%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Borgers%20JS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJessica%2BSW%2BBorgers%2B) * [ORCID record for Jessica SW Borgers](http://orcid.org/0000-0002-6478-7821 "Open in new tab") Victoria Sorensen University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Victoria%2BSorensen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sorensen%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AVictoria%2BSorensen%2B) * [ORCID record for Victoria Sorensen](http://orcid.org/0009-0003-8695-1498 "Open in new tab") Katherine Foley University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Katherine%2BFoley%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Foley%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKatherine%2BFoley%2B) Katherine M Kichula University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Katherine%2BM%2BKichula%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kichula%20KM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKatherine%2BM%2BKichula%2B) * [ORCID record for Katherine M Kichula](http://orcid.org/0000-0002-9817-3043 "Open in new tab") Martin D McCarter University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Martin%2BD%2BMcCarter%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=McCarter%20MD&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMartin%2BD%2BMcCarter%2B) * [ORCID record for Martin D McCarter](http://orcid.org/0000-0001-8174-1713 "Open in new tab") Sapna P Patel University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sapna%2BP%2BPatel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Patel%20SP&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASapna%2BP%2BPatel%2B) Kasey L Couts University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kasey%2BL%2BCouts%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Couts%20KL&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKasey%2BL%2BCouts%2B) * [ORCID record for Kasey L Couts](http://orcid.org/0000-0002-2088-2229 "Open in new tab") William A Robinson University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=William%2BA%2BRobinson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Robinson%20WA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWilliam%2BA%2BRobinson%2B) Richard P Tobin University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Richard%2BP%2BTobin%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tobin%20RP&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARichard%2BP%2BTobin%2B) * [ORCID record for Richard P Tobin](http://orcid.org/0000-0003-3890-4534 "Open in new tab") Paul J Norman University of Colorado Anschutz Medical Campus * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Paul%2BJ%2BNorman%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Norman%20PJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APaul%2BJ%2BNorman%2B) * [ORCID record for Paul J Norman](http://orcid.org/0000-0001-8370-7703 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.18.26363442v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1304735/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.18.26363442v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1304735/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.18.26363442v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1304735/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.09.18.26363442v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1304735/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.18.26363442v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1304735/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.18.26363442v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1304735/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Natural killer (NK) cells at the maternal-fetal interface harbor a specialized decidual phenotype that promotes placentation and immune tolerance. Although it has been postulated that tumors can exploit similar NK cell programs to augment the tumor microenvironment, this mechanism has not been investigated in melanoma. Using flow cytometry and multiplex immunohistochemistry, we identified CD56BrightCD16−CD49a+CD9+ decidual-like NK (dl-NK) cells within melanoma tumors; these cells were rare or absent in peripheral blood from either patients with melanoma or healthy donors. These dl-NK cells were detected within and surrounding melanoma tumors in both male and female patients and across melanoma subtypes and across primary, lymph node, and distant metastatic sites. In an exploratory cohort of patients treated with tumor-infiltrating lymphocyte therapy, higher dl-NK frequency was observed in the patient with progressive disease. Because CD9 is a defining feature of decidual NK cells, we examined the relationship of CD9 with the dl-NK phenotype. Tumor CD9 expression was positively associated with intratumoral dl-NK frequency (Pearson rho = 0.40, p = 0.056). Direct co-culture of healthy donor NK cells with CD9-expressing melanoma cells induced robust CD9 acquisition by CD56Bright NK cells, whereas separation by a transwell abrogated this effect, demonstrating a requirement for direct cell-cell interaction. Collectively, these findings identify a dl-NK cell population within melanomas and suggest that direct interactions with melanoma cells may contribute to acquisition of this phenotype, revealing a potential immunologic parallel between the melanoma microenvironment and the maternal-fetal interface. ### Competing Interest Statement Conflicts of Interest: Dr. Sapna Patel has the following conflicts of interest: Institutional clinical trial support: 7 Hills, Foghorn Therapeutics, Ideaya, Immatics, Immunocore, InxMed, iOnctura, Linnaeus, Lyvgen Biopharma, Novartis, Provectus Biopharmaceuticals, Replimune, Seagen, Syntrix Bio, TriSalus Life Sciences. Advisory board, steering committee, data safety monitoring board, consulting: Bristol Myers Squibb, Cardinal Health, Castle Biosciences, Clinical Education Alliance, Daiichi Sankyo, Delcath, Fortvita, Ideaya, Immatics, Immunocore, IO Biotech, Ipsen, Jazz Pharmaceuticals, Moderna, MSD, Natera, Novartis, Obsidian, OncoSec, Pfizer, Regeneron, Replimune, Scancell, Sun Pharma, T3 Pharmaceuticals, TriSalus Life Sciences, Veda Trials, Vindico Medical. Dr. Martin McCarter has the following conflicts of interest: Research funding from Taiho. Medical Consulting for Astra-Zenaca and Iovance. The remaining authors have no conflicts of interest to declare. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Colorado Multiple Institutional Review Board gave ethical approval for this work. Healthy donor peripheral blood mononuclear cells were obtained from the Human Immune Tissue Network Biobank by the University of Colorado Clinical and Translation Research Center under the University of Colorado Multiple IRB protocol #17-2159. Plateletpheresis leukoreduction filters were purchased from Vitalant Blood Center (Denver, CO, USA). Melanoma blood and tumor samples were collected from the University of Colorado Hospital under the Melanoma Biorepository at the University of Colorado Cancer Center IRB protocol #05-0309. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present study are available upon reasonable request to the authors ## Funder Information Declared This work was supported by Golfers Against Cancer and the National Institutes of Health, R21 CA297312, R01 AI158410 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.18.26363442v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.20.26363509v1 "SystematIc StudY of Patients with atHerosclerotic neUrovascular Stenoses \(SISYPHUS\): Study Protocol for a Prospective Observational Cohort Evaluating 3D Rotational Angiography and Final Implant Quality in Carotid Stenting")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.19.26363468v1 "Compound climate extremes, socioeconomic conditions and human mobility influence dengue dynamics heterogeneously across Vietnam") Posted September 21, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.18.26363442v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/21/2026.09.18.26363442.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.18.26363442v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.09.18.26363442v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/21/2026.09.18.26363442.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Decidual-Like Natural Killer Cells Are Enriched in Melanomas and Acquire CD9 Through Melanoma Cell Contact Natalie A Vandeven, Christopher E Collora, Claire Muckle, Sofia Celli, Jessica SW Borgers, Victoria Sorensen, Katherine Foley, Katherine M Kichula, Martin D McCarter, Sapna P Patel, Kasey L Couts, William A Robinson, Richard P Tobin, Paul J Norman medRxiv 2026.09.18.26363442; doi: https://doi.org/10.64898/2026.09.18.26363442 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.18.26363442v1%26text%3DDecidual-Like%2520Natural%2520Killer%2520Cells%2520Are%2520Enriched%2520in%2520Melanomas%2520and%2520Acquire%2520CD9%2520Through%2520Melanoma%2520Cell%2520Contact "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.18.26363442v1%26t
## Related Clinical Research

- [Methodological considerations when defining CBL (11q23.1-3) as a prognostic biomarker in stage II](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-methodological-considerations-in-defining-cbl-as-a-prognostic-biomarker-in.md)
- [Immune-pressure redistribution as a framework for resistance to PD-1/PD-L1 blockade](https://medichelpline.com/clinical-feed/pubmed-42763389.md) (DOI: 10.1186/s12943-026-02786-4)
- [LongPhase-TO: tumor-only long-read method for somatic haplotype reconstruction and variant recalib](https://medichelpline.com/clinical-feed/biorxiv-8-somatic-haplotype-reconstruction-and-variant-recalibration-from-tumor-only-long.md)
- [Cross-species spatial profiling implicates progranulin in immune-suppressive niches of brain metas](https://medichelpline.com/clinical-feed/biorxiv-0-cross-species-spatial-profiling-links-progranulin-to-an-immune-suppressive.md)
- [Lived Experience in Rare Disease Research: Shaping Outcomes for Patients](https://medichelpline.com/clinical-feed/plos-medicine-0-living-with-a-rare-disease-why-lived-experience-must-shape-research.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.